Skip to content
Peptigraph home
Shop Peptides50% off*

Is Survodutide Legal? FDA, Compounding and WADA Status

Survodutide's FDA status, compounding rules and anti-doping status, with a dated timeline of every change we track.

Medical review pendingGLP-1 / glucagon dual agonistUpdated
FDA status
Not approved
Investigational · phase 3
PCAC vote
Not reviewed
not on the Jul 2026 PCAC agenda
WADA
Prohibited (S0)
In and out of competition
Not legal adviceStatus reflects public FDA and WADA records on the date shown. Rules differ by country and state.

Current status

Investigational · phase 3

No. Survodutide is investigational (investigational · phase 3) and not approved for any use.

Survodutide: regulatory status by country
CountryStatusSource
United StatesNo approved product foundNo FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "survodutide" returned no matches on 2 Oct 2026.api.fda.govchecked 2 Oct 2026

Timeline

  1. FDA warning letters to five research-peptide sellersEnforcement
Every peptide on the FDA tracker

Compounding and research-use sellers

  • Category 2 is the FDA's list of bulk substances it flagged as raising significant safety concerns. Compounding pharmacies are not expected to compound from them while they are on it.
  • The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which substances belong on the 503A bulks list that pharmacies may compound from. Its votes are advice; the FDA decides.
  • "Research use only" products are sold outside these rules and are not checked by the FDA for identity, purity or dose.

Sport and drug testing

Prohibited by WADA (S0)

Survodutide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change.

Outside the US

Rules differ by country. What each regulator's own records show, with the date we checked:

Survodutide: regulatory status by country
CountryStatusSource
United KingdomNo approved product foundNo approved product found in an emc (UK SmPC compendium) search for "survodutide" on 2 Oct 2026.medicines.org.ukchecked 2 Oct 2026
CanadaNo approved product foundNo product found in a Health Canada Drug Product Database search for ingredient "survodutide" on 2 Oct 2026.health-products.canada.cachecked 2 Oct 2026
AustraliaNo approved product foundNo approved product found in an ARTG search for "survodutide" on 2 Oct 2026.tga.gov.auchecked 2 Oct 2026
European UnionNo centrally authorised EU medicine foundEMA medicines list, searched 2 Oct 2026ema.europa.euchecked 2 Oct 2026

What regulator databases show for survodutide

The openFDA Drugs@FDA search for survodutide as an active ingredient found no application.[2]

Health Canada's drug product database search returned no active-ingredient records for survodutide.[4]

The Australian Register of Therapeutic Goods search for survodutide had no matching results.[5]

The UK emc search for survodutide returned no search results.[3]

Phase 3 status

The phase 3 trial report calls survodutide an investigational dual agonist.[8]

The first phase 3 registry record lists its primary completion date as 2025-12-02.[9]

The phase 3 trial in people with diabetes lists its primary completion date as 2025-12-12.[10]

Common questions

Is survodutide FDA approved?

No application for survodutide appears in the cached Drugs@FDA search.[2]

Is Survodutide legal to buy?

It is not an approved drug. Online sellers label it "for research use only, not for human use"; the FDA sent warning letters to five such sellers on 24 Aug 2026. Whether a pharmacy may compound it depends on its FDA bulk-substance status. Rules differ by country.

Is Survodutide banned by WADA?

Yes. Prohibited by WADA (S0), in and out of competition.

What is the survodutide phase 3 status?

The registry lists primary completion for the first phase 3 trial as 2025-12-02, and the cached registry record has no posted results.[9]

More on Survodutide

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.How to injectSites, syringe types and hygiene, step by step.BenefitsClaimed benefits next to what published studies measured.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "survodutide" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  3. 3United Kingdom: No approved product found in an emc (UK SmPC compendium) search for "survodutide" on 2 Oct 2026.Electronic Medicines Compendium (UK) · 2026medicines.org.ukAccessed 2 Oct 2026
  4. 4Canada: No product found in a Health Canada Drug Product Database search for ingredient "survodutide" on 2 Oct 2026.Health Canada · 2026health-products.canada.caAccessed 2 Oct 2026
  5. 5Australia: No approved product found in an ARTG search for "survodutide" on 2 Oct 2026.Therapeutic Goods Administration (Australia) · 2026tga.gov.auAccessed 2 Oct 2026
  6. 6EMA medicines export (centrally authorised medicines) (searched 2 Oct 2026)European Medicines Agency · 2026ema.europa.euAccessed 2 Oct 2026
  7. 7FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  8. 8Survodutide Once Weekly for the Treatment of Adults with Obesity.The New England journal of medicine · 2026PMID 42253238Accessed 2 Oct 2026
  9. 9A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity Without Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
  10. 10A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes MellitusClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.